Business
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Presented positive complete results from the MISSION Phase 2 trial evaluating zetomipzomib in patients with lupus nephritis at ASN’s Kidney Week 2022 Annual
About this update from Kezar Life Sciences, Inc.
[{"type":"text","content":"\n\nPresented positive complete results from the MISSION Phase 2 trial evaluating zetomipzomib in patients with lupus nephritis at ASN’s Kidney Week 2022 Annual Meeting\n\n\nReceived FDA clearance of IND for zetomipzomib for the treatment of autoimmune hepatitis\n\n\nCash, cash equivalents and marketable securities totaled $290.4 million as of September 30, 2022\n\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nKezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results for the third quarter ended September 30, 2022 and provided a business update.\n\n“In the third quarter, the team at Kezar continued its tradition of strong execution across our clinical and portfolio development plans,” said John Fowler, Kezar’s Co-founder and Chief Executive Officer. “Supported by the results from the MISSION study, our conviction remains high that zetomipzomib has the potential to be a non-immunosuppressive, steroid-sparing treatment for patients with lupus and lupus nephritis. In addition, our recently announced development plan in autoimmune hepatitis underscores our belief that zetomipzomib can help patients across a diverse range of autoimmune diseases. In parallel, we are excited by progress in our protein secretion inhibition platform and look forward to our SITC poster presentation tomorrow on KZR-540, an oral small molecule that selectively blocks PD-1 expression.”\n\nZetomipzomib: Selective Immunoproteasome Inhibitor\n\nMISSION – Phase 2 clinical trial of zetomipzomib in patients with active lupus nephritis (LN) (NCT03393013)\n\n\nKezar presented positive complete results for the 37-week Phase 2 MISSION clinical trial at the American Society of Nephrology’s (ASN) Kidney Week 2022 Annual Meeting.\n\n\nDuring the 24-week treatment period, patients received 60 mg of zetomipzomib subcutaneously once weekly (first dose of 30 mg) in addition to stable background therapy. End-of-treatment assessments occurred at Week 25 (EOT), with a safety follow up period and completion of the study at Week 37 (EOS). Patients in the MISSION Phase 2 clinical trial received zetomipzomib without induction therapy, which represents a difference from other recently published clinical trials in LN. The primary e...